Sponsored by Shore Thing Media*

Markets are breathing a little easier after Trump walked back his tough tariff talk — exactly like I predicted. Meanwhile, I’ve got my eye on a biotech that’s been ripping lately and just got a fresh cash injection to back up its cancer-fighting tech. This one’s worth watching today.

TODAY’S TOP ALERT! 

 CERo Therapeutics (Nasdaq: CERO)

Good morning, Folks!

Quick reminder: I’m LIVE today in for Mission 2 Million trading at 9:20AM EST — join me HERE (stop by and introduce yourself👋).

Now… on the eve of “Liberation Day” earlier this month (can you believe it hasn’t even been a month??), I wrote to you with a prediction…

I noted that President Trump loves to be up in the polls, and “Poll after poll shows Americans want more focus on lowering prices and less on levying tariffs.”

I added, “the President also strongly gauges his success by that of the stock market,” which had responded very poorly to tough tariff talk.

My conclusion? “If tariffs do come out big tomorrow, I think the goal will be to gain concessions, and that they’ll quickly notch down.”

Last night, we got this:

President Trump said the current 145% China tariff rate is “very high, and it won’t be that high. … No, it won’t be anywhere near that high. It’ll come down substantially. But it won’t be zero.”

I’d say my prediction is holding up well!

The markets have responded positively to the walkback so far, and we’ll see if that carries through to the weekend.

In the meantime, I’m continuing to look for “tactical trade” ideas I think can outperform in the short run.

Yesterday’s idea surged nearly 30% before the sellers took over, reminding us that it’s critical to watch your trades very closely in this market.

Right now I’m staring down another idea that has absolutely ripped over the past week.

Pull up the chart for CERo Therapeutics Holdings, Inc. (CERO) and feast your eyes on that sweet 37% gain.

The stock is up again in the pre-market and I’m loving what I see on the very short term hourly:

That’s a readout from my favorite tool for gauging momentum, the AI-powered go/no go algorithm.

As I mentioned, it’s critical to watch your trades in this market, and though the White House is converging on a “deescelation” message in the trade war, we obviously can’t rule out developments from left field.

On the upside, I would watch the $0.85 level for CERO, which is above resistance from earlier this month. If we top that, the stock could see a big gain today.

But on the downside, a move below $0.73 signal a new downtrend, and then I’d sit on sidelines and wait for a better trend.

👉  CERO is TODAY’S #1 ALERT 👈

Here’s what the company itself has going on…

CERO is a preclinical biopharma company that “focuses on genetically engineering immune cells to fight cancer.” 

Headquartered in San Francisco, its mission is to “discover, translate, and deliver pioneering curative cell therapies that incorporate multiple forms of tumor clearance into single T cells.”

Its core technology is the CER T-cell platform, which targets both hematologic and solid-tumor cancers.

You can read more about the platform here, but in brief, it is based on a new class of engineered cells called chimeric engulfment receptors (CERs).

These are introduced into T cells, allowing “tumor recognition via an ‘Eat Me’ signal present on tumor cells” and stimulating both the innate and adaptive immune systems.

In preclinical testing, the platform has demonstrated “tumor-killing capabilities for blood system and solid tumor cancers – Leukemia (AML), lung cancer (NSCLC), Ovarian Cancer, and B-cell Malignancies.”

The company believes “the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy.”

In November, the FDA cleared CERO’s IND application “for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML).”

And on March 31, it received an additional IND clearance for CER-1236 “for a Phase 1 clinical trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.”

The company is first pursuing the Phase 1 trial for AML, revealing on April 9 that the trial will be led by an assistant professor of leukemia at The University of Texas MD Anderson Cancer Center, which CEO Chris Ehrlich calls “one of the most renowned cancer centers in the United States.”

Patient enrollment is currently underway, and CERO expected dosing of the first patient in the first half of 2025.

In the second half of the year, the company expects to begin a Phase 1 trial in solid tumors, as well as to produce initial patient data from both the AML and solid-tumor trials.

Most of this science is beyond my expertise, but it’s encouraging to see CERO has attracted investments from institutional heavyweights such as Sequoia Capital, Arch Venture Partners, and Altitude Life Science Ventures.

And just this week, the investment bank D. Boral Capital put a “BUY” rating on CERO with an $11.00 price target. Folks, that’s nearly 1,300% over yesterday’s closing price.

Lastly, I should note that news broke yesterday that the company had secured up to $8 million in Series D financing, which it “plans to utilize the proceeds to leverage its recent FDA IND allowances in liquid and solid tumors, complete site activation at MD Anderson Cancer Center (MDACC), and accelerate additional site activations. The funding will also help address Nasdaq shareholders equity requirements and extend operational runway.”

That news could well give it another big leg up today.

As always, though, these are just my conclusions. Be sure to do your own homework, starting with this January 2025 investor presentation and the company’s slick website.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: CERO is pioneering a therapy that in preclinical testing demonstrated tumor-killing capabilities for blood system and solid tumor cancers.

Its stock is up 37% over the past week and it’s climbing again in the pre-market.

Keep CERO at the top of your radar today to see where it goes!

To Your Success,

Jeff Bishop

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty thousand dollars (cash) from Shore Thing Media for advertising CERo Therapeutics Holdings, Inc for a one day marketing program on April 24, 2025. It might seem obvious, but while our client claims not to own any shares in CERo Therapeutics Holdings, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into CERo Therapeutics Holdings, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.